Solid Biosciences shares plunge 45% as clinical study put on hold

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Gene therapy stocks tank after leading scientist reveals safety concerns; Solid Bioscience down 15%

Shares of gene therapy companies fell sharply Tuesday, after a report by a prominent scientist revealed the safety concerns that led him to resign recently from Solid Bioscience Inc.’s scientific advisory board. Gene therapy researcher James Wilson, a giant in the field, quit the board ahead of its IPO because of the possible risks of high systemic dosing of AAV, the company’s delivery system, according to the company’s IPO prospectus. Just hours before Solid Bioscience priced its IPO last week, it revealed that the U.S. Food and Drug Administration had placed a partial clinical hold on the company’s lead product, SGT-001, a treatment for Duchenne muscular syndrome that involves high-dose AAV gene therapy. On Monday, Wilson and his team published a paper that revealed that monkeys and pigs used in an animal trial were sent into toxic crisis when given a high dose AAV delivery of a corrective gene. Solid Bioscience shares led the decliners, sliding 16%, AveXis Inc. shares were down 10% and Audentes Therapeutics Inc. shares slid about 4%. The S&P 500 was down 0.9%.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply